The Canadian Agency for Drugs and Technologies in Health (CADTH) Canadian Drug Expert Committee (CDEC) has issued a positive recommendation that TAKHZYRO® (lanadelumab injection) be reimbursed by public drug plans for routine prevention of HAE attacks in adolescents and adults (12 years of age and older). “As a physician who treats patients with HAE, I [...]
KalVista Pharmaceuticals, Inc. expects to complete enrollment for the KVD900 Phase 2 clinical trial before year-end 2019 and to provide data in 2020. “We are pleased with the rate of enrollment of our Phase 2 clinical trial of KVD900 in HAE patients,” said Andrew Crockett, CEO of KalVista. “Our plan to recruit patients primarily in [...]
The 83rd member of the HAE International family is South Korea. The patient organization HAE Korea has just been established – and we have three HAE knowledgeable physicians and two HAE knowledgeable hospitals on the map. Have a look at https://haei.org/hae-member-countries/south-korea.
Takeda Pharmaceutical Company Limited announces new data that further investigate the long-term safety and efficacy of TAKHZYRO® (lanadelumab-flyo) injection in patients with HAE 12 years of age and older studied in the ongoing Phase 3 HELP (Hereditary Angioedema Long-term Prophylaxis) Study™ Open-label Extension (OLE). The analyses, being presented at the 2019 American College of Allergy, Asthma [...]
BioCryst Pharmaceuticals, Inc. announces the 48-week results from its APeX-S and APeX-2 trials and comprehensive market research which support the significant commercial opportunity for oral, once daily BCX7353 in HAE. “The 48-week clinical trial data we now have from APeX-S and APeX-2 highlight the control patients are having over their attacks with oral, once daily [...]
Announcing the financial results for the third quarter ended 30 September 2019 BioCryst Pharmaceuticals, Inc., President and CEO Jon Stonehouse says: “BioCryst is positioned for a transformational 2020, with the potential approval and launch of BCX7353 in the U.S. and regulatory filings for BCX7353 in Japan and Europ. We are also actively evaluating multiple approaches to add capital [...]
Today HAE International welcomes member number 82: Georgia. The HAE patients of Georgia are represented by David Ramazashvili.
BioCryst Pharmaceuticals, Inc. has licensed commercialization rights in Japan to Torii Pharmaceutical, Co. for BCX7353, an oral, once-daily treatment for the prevention of HAE attacks. “We are excited to partner with Torii to accelerate access for Japanese patients to BCX7353,” said Jon Stonehouse, president and CEO of BioCryst. “Torii has a strong and recent history [...]
HAE Lithuania has signed up as the 81st member organization of HAE International. Laura Malinauskiene is the national contact for Lithuania.
We are happy to inform you that HAE International has been joined by country no. 80. A warm welcome to Estonia, represented by national contact Kristal Kaljula.
HAE International is a global non-profit network of member organizations dedicated to raising awareness of hereditary angioedema and improving the lives of people with HAE.
HAE International (HAEi)
10560 Main Street, Ste PS40
Fairfax City, VA 22030
United States of America
gro.ieah@ofni
HAE International (HAEi)
Vejlevej 16, 1.
8700 Horsens
Denmark
gro.ieah@ofni